6 completed, 4 terminated. 8 Phase 2, 5 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 8 | Completed 4, Terminated 4 |
| Phase 1 | 5 | Completed 4, Terminated 1 |
Follow Processa Pharmaceuticals: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Phase 2 Study of PCS6422 With Capecitabine in Patients With Advanced or Metastatic Breast Cancer PCS6422 and capecitabine, Capecitabine - Breast Cancer, TNBC - Triple-Negative Breast Cancer | Phase 2 | Terminated | Processa Pharmaceuticals | 20 | 2024-10-02 | 2026-10-06 |
| Safety, PK and Efficacy of PCS12852 on Gastric Emptying Rate in Patients With Moderate to Severe Gastroparesis PCS12852, Placebo - Gastroparesis | Phase 2 | Completed | Processa Pharmaceuticals | 25 | 2022-03-09 | 2026-10-22 |
| A Study of the Safety and PK of PCS6422 (Eniluracil) with Capecitabine in Patients with Advanced, Refractory GI Tract Tumors PCS6422 and capecitabine - Advanced Cancer, Refractory Cancer | Phase 1 | Completed | Processa Pharmaceuticals | 23 | 2021-06-18 | 2024-10-10 |
| A Clinical Trial to Evaluate PCS499 in Treating Ulcerations in Patients Who Have Necrobiosis Lipoidica PCS499, placebo - Necrobiosis Lipoidica | Phase 2 | Terminated | Processa Pharmaceuticals | 4 | 2021-04-12 | 2023-08-03 |
| A Study to Evaluate the Safety and Tolerability of PCS499 for the Treatment of Necrobiosis Lipoidica PCS499 - Necrobiosis Lipoidica | Phase 2 | Completed | Processa Pharmaceuticals | 12 | 2018-11-07 | 2026-10-22 |
| Study to Evaluate the PK of Single and Optional Multiple Dosing Regimens of MR Formulations of PCS499 Compared to Trental® Administered to Healthy Subjects PCS499, Trental - Healthy | Phase 1 | Completed | Processa Pharmaceuticals | 18 | 2018-02-26 | 2019-02-12 |
| RX-3117 in Combination With Abraxane® in Subjects With Metastatic Pancreatic Cancer RX-3117 - Metastatic Pancreatic Cancer | Phase 1 / Phase 2 | Completed | Processa Pharmaceuticals | 46 | 2017-10-02 | 2023-12-06 |
| Dose-Finding and Safety Study for Oral Single-Agent to Treat Advanced Malignancies RX-3117 - Solid Tumor, Metastatic Bladder Cancer | Phase 1 / Phase 2 | Completed | Processa Pharmaceuticals | 127 | 2013-12-01 | 2023-12-06 |
| Open Label Extension Study of HT-100 in Patients With DMD HT-100 - Duchenne Muscular Dystrophy | Phase 2 | Terminated | Processa Pharmaceuticals | 17 | 2013-10-01 | 2020-09-03 |
| Safety, Tolerability, and Pharmacokinetics of Single and Multiple Doses of HT-100 in Duchenne Muscular Dystrophy HT-100 - Duchenne Muscular Dystrophy | Phase 1 / Phase 2 | Terminated | Processa Pharmaceuticals | 17 | 2013-05-01 | 2020-09-03 |
Muscular Dystrophy, Duchenne (2) · Necrobiosis Lipoidica (2) · Neoplasms (2) · Breast Neoplasms (1) · Gastroparesis (1) · Neoplasm Metastasis (1) · Pancreatic Neoplasms (1) · Stomach Neoplasms (1) · Triple Negative Breast Neoplasms (1) · Urinary Bladder Neoplasms (1)
Capecitabine (2) · fluorocyclopentenylcytosine (2) · Albumin-Bound Paclitaxel (1) · Pentoxifylline (1) · Serotonin 5-HT4 Receptor Agonists (1) · eniluracil (1)
United States (9) · United Kingdom (1)
Diana M Escolar, MD (2) · Ely Benaim, MD (2) · Maya Das, MD (1) · Mridula George, MD (1) · Richard McCallum, MD (1) · Sharan Sidhu, MBChB (1) · Sian Bigora, Pharm. D (1) · Sian Bigora, PharmD (1)